NCT02238119已完成2 期
A Randomised, Double-blind, Double-dummy, Crossover Efficacy and Safety Comparison of 6-week Treatment Periods of the Free Combination of Tiotropium Inhalation Powder Capsule (18 μg) + Formoterol Inhalation Powder Capsule (12 μg) QD, Tiotropium Inhalation Powder Capsule (18 μg) QD and Formoterol Inhalation Powder Capsule (12 μg) BID in Patients With COPD
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 74
- 主要终点
- Change in area under the curve from pre-dose to 12 hours of the forced expiratory volume in one second (FEV1 AUC0-12h)
研究概览
简要总结
Study to evaluate the lung function response to the free once-daily combination of tiotropium + formoterol compared to formoterol BID and tiotropium QD
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients had to sign an informed consent consistent with International Conference on Harmonization Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, which included medication washout and restrictions
- •All patients had to have a diagnosis of chronic obstructive pulmonary disease and had to meet the following spirometric criteria:
- •Patients had to have relatively stable moderate to severe airway obstruction with an FEV1 ≤ 60% of predicted normal and FEV1 ≤ 70% of FVC (Visits 1 and 2)
- •Male or female patients 40 years of age or older
- •Patients had to be current or ex-smokers with a smoking history of more than 10 pack-years (Patients who had never smoked cigarettes had to be excluded)
- •Patients had to be able to perform technically acceptable pulmonary function tests and had to be able to maintain records (Patient Daily Diary Record) during the study period as required in the protocol
- •Patients had to be able to inhale medication in a competent manner from the HandiHaler® device, the Blue Inhaler device and from a metered dose inhaler (MDI)
排除标准
- •Patients with significant diseases other than COPD had to be excluded. A significant disease was defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
- •Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis if the abnormality defined a disease listed as an exclusion criterion
- •All patients with an serum glutamate oxaloacetate transaminase (SGOT) > 80 IU/L, serum glutamate pyruvate transaminase (SGPT) > 80 IU/L, bilirubin > 17 μmol/L or creatinine > 110 μmol/L (males) / 95 μmol/L (females) had to be excluded regardless of clinical condition
- •Patients with a recent history (i.e., six months or less) of myocardial infarction
- •Patients with any cardiac arrhythmia requiring drug therapy or who had been hospitalised for heart failure within the past three years
- •Patients with a history of cancer within the last five years. Patients with treated basal cell carcinoma were allowed
- •Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction.
- •Patients with prostatic hypertrophy controlled by medication were allowed
- •Patients with known narrow-angle glaucoma
- •Patients with a history of asthma, allergic rhinitis or who had a total blood eosinophil count ≥600 mm3
- •Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis
- •Patients with known active tuberculosis
- •Patients with a history of and/or active significant alcohol or drug abuse. See exclusion criterion No.
- •Patients who had undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons had to be evaluated as per exclusion criterion No. 1
- •Patients who completed a pulmonary rehabilitation program in the six weeks prior to the Screening Visit (Visit 1)
- •Patients who regularly used daytime oxygen therapy
- •Patients who had taken an investigational drug within one month or six half lives (whichever is greater) prior to Screening Visit (Visit 1)
- •Patients who were treated with beta-blocker medications. Note: cardioselective beta blocker eye medications (e.g. Betoptic®) for treatment of non-narrow angle glaucoma were allowed
- •Patients who were treated with oral beta-adrenergics
- •Patients who were treated with cromolyn sodium or nedocromil sodium
- •Patients who were treated with antihistamines (H1 receptor antagonists), antileukotrienes or leukotriene receptor antagonists for asthma or excluded allergic conditions. See exclusion criterion No. 9
- •Patients using oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day
- •Patients with known hypersensitivity to anticholinergic drugs, beta-adrenergics, lactose or any other components of the inhalation capsule delivery systems
- •Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception for the previous 3 months (i.e. oral contraceptives, intrauterine devices, diaphragm or subdermal implants e.g., Norplant®)
- •Patients with previous participation (receipt of randomised treatment) in this study
研究组 & 干预措施
tiotropium + formoterol
Experimental
干预措施: Tiotropium + formoterol combination (Drug)
tiotropium
Active Comparator
干预措施: Tiotropium (Drug)
formoterol
Active Comparator
干预措施: Formoterol (Drug)
结局指标
主要结局
Change in area under the curve from pre-dose to 12 hours of the forced expiratory volume in one second (FEV1 AUC0-12h)
时间窗: after 6 weeks of each treatment
Change in FEV1 AUC0-24h
时间窗: after 6 weeks of each treatment
次要结局
- Change in FEV1 AUC12-24h(after 6 weeks of each treatment)
- Change in AUC of the forced vital capacity (FVC AUC0-12h)(after 6 weeks of each treatment)
- Change in FVC AUC0-24h(after 6 weeks of each treatment)
- Change in FVC AUC12-24h(after 6 weeks of each treatment)
- Change in peak FEV1 response(after 6 weeks of each treatment)
- Change in trough FEV1 response(after 6 weeks of each treatment)
- Change in peak FVC response(after 6 weeks of each treatment)
- Change in trough FVC response(after 6 weeks of each treatment)
- Individual FEV1measurements at each time point(up to 6 weeks)
- Individual FVCmeasurements at each time point(up to 6 weeks)
- Peak expiratory flow rate (PEFR)(weeks 4 to 6 of each treatment period)
- Number of inhalations of rescue salbutamol therapy used per day(weeks 4 to 6 of each treatment period)
- Assessment of daytime COPD symptom score rated on a 6-point rating scale(weeks 4 to 6 of each treatment period)
- Assessment of nighttime COPD symptom score rated on a 5-point rating scale(weeks 4 to 6 of each treatment period)
- Number of patients with adverse events(up to 23 weeks)
研究者
相似试验
已完成
2 期
Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT02242253Boehringer Ingelheim97
已完成
4 期
A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to InhalePulmonary Disease, Chronic ObstructiveNCT04223843Boehringer Ingelheim213
已完成
3 期
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD PatientsPulmonary Disease, Chronic ObstructiveNCT01969721Boehringer Ingelheim229
已完成
3 期
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT00281567Boehringer Ingelheim76
已完成
4 期
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.Pulmonary Disease, Chronic ObstructiveNCT00563381Boehringer Ingelheim7,376